First mRNA Vaccine for Elephants Shows Evidence of Protection Against Deadly EEHV
Key Insights
After more than 15 years of research, Baylor College of Medicine and Houston Zoo (search) published the first peer-reviewed evidence that an experimental mRNA vaccine may protect young Asian elephants from EEHV.
Two companion papers in the Journal of Virology describe the vaccine's development and the first clinical evidence that vaccinated elephants withstood natural EEHV1A infection without severe disease.
On June 18, 2024, Houston Zoo (search)'s Asian elephant Tess became the first elephant ever to receive the experimental EEHV mRNA vaccine (search).
After more than 15 years of collaborative research, Baylor College of Medicine (BCM) and Houston Zoo (search) have reached a major milestone in the fight against elephant endotheliotropic herpesvirus (search) (EEHV), publishing the first peer-reviewed evidence that an experimental mRNA vaccine may help protect young Asian elephants from one of the deadliest diseases facing the species.
Two companion papers published in the Journal of Virology describe both the development and evaluation of the world's first mRNA vaccine for elephants and the first evidence that elephants receiving this vaccination can successfully withstand natural infection with EEHV1A without developing severe hemorrhagic disease.
"This milestone represents years of dedication by researchers, veterinarians and elephant care professionals determined to protect future generations of elephants," said Lisa Peterson, president and CEO of Houston Zoo (search). "EEHV has been one of the greatest threats facing young Asian elephants, and these findings offer real hope and bring us one step closer to changing the future for elephants."
A 15-Year Partnership Bears Fruit
The research builds on a partnership established in 2009 between Houston Zoo (search) and BCM virologist Dr. Paul Ling, following the loss of a young Houston Zoo elephant to EEHV. Over the years, the collaboration has led to major advancements in EEHV diagnostics, treatment protocols, and prevention strategies.
The virus remains the leading cause of death in juvenile Asian elephants in North American zoos and poses an ongoing threat to elephant calves across Asia. While advances in early detection and treatment have saved lives, an effective vaccine has long been considered one of the most important missing tools in the fight against EEHV.
A historic milestone occurred on June 18, 2024, when Houston Zoo (search)'s Asian elephant Tess became the first elephant ever to receive the experimental EEHV mRNA vaccine (search). Houston Zoo elephants Winnie and Teddy also participated in the vaccine study.
Vaccine Development and Immune Response
The first study evaluated a multi-antigen mRNA vaccine in nine Asian elephants at five zoological institutions, including Houston Zoo (search). Researchers found the vaccine generated sustained immune responses against key viral proteins.
"These studies provide the first published evidence that vaccination can induce protective immune responses against EEHV and may prevent the severe disease associated with primary infection," said Dr. Paul D. Ling, professor of molecular virology and microbiology at Baylor College of Medicine. "While additional research is still needed, this represents a significant step toward protecting vulnerable elephant calves from a disease that has challenged the elephant community for decades."
Clinical Protection in Naturally Infected Elephants
A companion study provided the first evidence of clinical protection. Two vaccinated juvenile elephants at Cincinnati Zoo later experienced natural EEHV1A infection, remained clinically healthy, required no medical intervention, and recovered without developing hemorrhagic disease.
The studies mark the first peer-reviewed publication describing administration of an mRNA vaccine in elephants and provide the first published evidence that an EEHV vaccine may prevent severe illness associated with primary infection.
Next Steps and Global Collaboration
What began as a research partnership between Houston Zoo (search) and Baylor College of Medicine more than 15 years ago has evolved into a global effort to combat one of the greatest threats facing elephants. While these studies mark a significant achievement, the work is far from complete. Researchers already are developing next-generation EEHV vaccines for Asian elephants and exploring vaccine approaches for African elephants.
Dr. Jeroen Pollet of Texas Children's Hospital was a key collaborator, helping produce the first vaccine batch. Dr. Lauren Farris, a postdoctoral researcher in the Ling lab at Baylor College of Medicine, led much of the vaccine evaluation work. Additional collaborators included partner zoos Cincinnati Zoo and Botanical Garden, Fort Worth Zoo and Rosamond Gifford Zoo, along with Johns Hopkins School of Medicine. Funding for these studies was provided by Houston Zoo (search), the International Elephant Foundation, and Colossal Biosciences (search).